home.aspx
 
EVENTS

Vital Signs EMS Conference
VITAL SIGNS EMS CONFERENCE
October 29-01, 2020
Vital Signs EMS Conference will be showcasing many of the extraordinary aspects of EMS and healthcare found only in Saratoga Springs. This event provided high quality and cutting edge EMS education by providing access to national and world-renowned educators through a forum that is accessible and af...

Internal Medicine for Primary Care
INTERNAL MEDICINE FOR PRIMARY CARE
October 30-01, 2020
The Internal Medicine for Primary Care conference will cover areas like Internal Medicine for Primary Care Physicians, Issues in Women's Health Cardio, Pulmonary for Primary Care Physicians, Neurology for the Non-Neurologist.

AbbVie

SHARESHARESHARE
At AbbVie, we believe the world needs new approaches to addressing today’s health issues — from life-threatening illness to chronic conditions. We combine advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people’s lives. With 28,000+ employees and medicines in over 170 countries, AbbVie is uniting the best of pharma and the boldness of biotech, to innovate end-to-end approaches that make a real difference in people’s lives.
SHARESHARESHARE

RELATED NEWS


The drug industry has come together in unprecedented collaborative efforts to tackle COVID-19. Now, as part of an R&D alliance, three big drugmakers are running a joint clinical trial to see whether their products can improve outcomes for severely ill patients. A recently launched clinical program, dubbed I-SPY, will test Amgen’s psoriasis med Otezla, Takeda’s hereditary angioedema therapy Firazyr and AbbVie’s experimental nonalcoholic steatohepatitis drug cenicriviroc to s...
FIERCEPHARMA
READ MORE

AbbVie and Harpoon Therapeutics have announced that the former will has licensed the B cell maturation antigen (BCMA)-targeting drug HPN217 for multiple myeloma from the pair’s drug discovery collaboration. AbbVie and Harpoon entered into a drug discovery collaboration in October 2017 to leverage the latter’s Tri-specific T cell Activating Construct (TriTAC) technology to discover T cell-focused immuno-oncology drugs. Financial terms of this collaboration were not publicly disclosed ...

READ MORE

US-based Dragonfly Therapeutics has announced it has signed a multi-target collaboration with AbbVie to advance immunotherapies created using its Tri-specific Natural Killer (NK) cell engager Therapies (TriNKET) technology for autoimmune and oncology indications. AbbVie has made an undisclosed upfront payment to Dragonfly, and has agreed to future success-based milestone and royalty payments. As a result of the agreement, AbbVie will have the option to license exclusive, global rights to develop...

READ MORE

AbbVie has received the US Food and Drug Administration (FDA) approval for Mavyret (glecaprevir / pibrentasvir) to lower the therapy period from 12 to eight weeks in hepatitis C (HCV) patients with cirrhosis. The indication for once-daily therapy is meant for treatment-naïve, compensated cirrhotic, chronic HCV patients across all genotypes (GT1-6). Previously, the drug secured FDA approval in August 2017 for eight-week, pan-genotypic therapy for treatment-naïve HCV patients without cir...

READ MORE

Pharma watchers have been awaiting House Speaker Nancy Pelosi’s drug pricing plan, and on Monday the industry got a peek at what Democrats are discussing to lower drug prices. The upshot? If the House leadership gets its way, it would devastate pharma's pricing power. The leaked document is outdated and the proposals could change, a senior aide told The Hill. The industry would put up fierce opposition, and Republicans could well balk, too. But the bullet points offer a glimpse into th...

READ MORE

AbbVie has axed its troubled lung cancer drug Rova-T, after another trial failure from the drug that is turning out to be an expensive flop, costing almost $10 billion so far. As it searched for new drugs to replace revenues lost from the patent expiry of its mega-blockbuster Humira, AbbVie snapped up Rova-T’s developer Stemcentrx in 2016 for $5.8 billion. But the gamble has not paid off after yet another trial disaster from the antibody-drug conjugate, full name rovalpituzumab tesirine. A...

READ MORE

AbbVie has announced the US Food and Drug Administration FDA approval of Rinvoq upadacitinib for moderate to severe active rheumatoid arthritis RA. In the SELECT programme, the oral JAK inhibitor met all primary and ranked secondary endpoints across a variety of patients with moderately to severely active rheumatoid arthritis, and significantly inhibited radiographic progression even without methotrexate. The study was one of the largest registrational Phase III programs in RA with approximately...

READ MORE

Lawmakers may have left the nations capital for summer vacation, but regulators at the FDA are staying busy. The agency churned out five approvals just last week from companies large and small and five more decisions are due by months end. Three of last weeks green lights opened the way for launches worth half a billion or more in annual sales. But the week started with a couple of OKs smaller on the sales side, if still significant for the organizations that developed them. Pretomanid, a tuberc...

READ MORE

Allergan has confirmed it will hive off two drugs so that AbbVies 63 billion dollars takeover offer could pass U.S. antitrust scrutiny. But recent regulatory decision and indecision on pharma deals has analysts worried whether that would be enough. In an investor Q and A published Tuesday, Allergan said it will sell brazikumab and Zenpep as part of the merger process, “irrespective of whether such divestitures are required by the regulators.” Those two have been suspected for-sale ta...

READ MORE

The Pharma industry cheered when the Trump administration introduced a proposal putting drug pricing rebates in the crosshairs. But like so many other drug pricing ideas over the years, the measure didnt go anywhere. Now, the administration is switching gears to importation. HHS on Wednesday presented a plan for bringing in cheaper drugs from Canada, an approach the industry staunchly opposes. It marks a major shift from previous policies on imports, but the plan itself might not do much to lowe...

READ MORE

EVENTS

Update CME - Internal Medicine & Primary Care
UPDATE CME - INTERNAL MEDICINE & PRIMARY CARE
October 29-01, 2020
Earn 30 CME Credits by attending our Update CME Internal Medicine and Primary Care Conference either in person or via live stream!Expert speakers from The University of Chicago, Johns Hopkins, and University of California, Los Angeles will be presenting on the latest clinical guidelines. We offer in...

Internal Medicine for Primary Care
INTERNAL MEDICINE FOR PRIMARY CARE
October 30-01, 2020
The Internal Medicine for Primary Care conference will cover areas like Internal Medicine for Primary Care Physicians, Issues in Women's Health Cardio, Pulmonary for Primary Care Physicians, Neurology for the Non-Neurologist.